Lilly's stock is down after sharing additional clinical data about its Alzheimer's disease drug candidate

Dow Jones2021-03-15

ShaShares of Eli Lilly & Co. $(LLY)$ were down 5.2% in premarket trading on Monday, two days after the drug maker said additional clinical-trial data reinforced the role its experimental Alzheimer's disease drug can play in slowing decline among people with early symptomatic forms of the disease. The data was published in the New England Journal of Medicine on Saturday, and it examined results from a Phase 2 study that found donanemab could reduce decline by 32% when compared against placebo at 76 weeks. Though the study met the primary endpoint, the researchers said that the secondary findings from the trial had mixed results. "If these results are confirmed in the larger study now in progress, donanemab could offer the potential for a disease-modifying therapy that can help patients maintain cognitive abilities and their independence longer," Dr. Howard Fillit, chief science officer of the Alzheimer's Drug Discovery Foundation, said in a statement. Lilly's stock is up 49.3% over the past year, while the broader S&P 500 has gained 58.9%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

kenneeth
2021-03-15
kenneeth
Test
HarimauZack
2021-03-15
HarimauZack
Nicceeee
1nu
2021-03-15
1nu
Nice

Leave a comment

3

14

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2119912637?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-03-15 19:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2119912637","market":"us","top_or_hot":-1,"title":"Lilly's stock is down after sharing additional clinical data about its Alzheimer's disease drug candidate","media":"Dow Jones","content":"<p>ShaShares of Eli Lilly &amp; Co. <a href=\"https://laohu8.com/S/LLY\">$(LLY)$</a> were down 5.2% in premarket trading on Monday, two days after the drug maker said additional clinical-trial data reinforced the role its experimental Alzheimer's disease drug can play in slowing decline among people with early symptomatic forms of the disease. The data was published in the New England Journal of Medicine on Saturday, and it examined results from a Phase 2 study that found donanemab could reduce decline by 32% when compared against placebo at 76 weeks. Though the study met the primary endpoint, the researchers said that the secondary findings from the trial had mixed results. \"If these results are confirmed in the larger study now in progress, donanemab could offer the potential for a disease-modifying therapy that can help patients maintain cognitive abilities and their independence longer,\" Dr. Howard Fillit, chief science officer of the Alzheimer's Drug Discovery Foundation, said in a statement. Lilly's stock is up 49.3% over the past year, while the broader S&amp;P 500 has gained 58.9%.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lilly's stock is down after sharing additional clinical data about its Alzheimer's disease drug candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLilly's stock is down after sharing additional clinical data about its Alzheimer's disease drug candidate\n</h2>\n\n<h4 class=\"meta\">\n\n2021-03-15 19:44 北京时间&nbsp;&nbsp;&nbsp;<strong>Dow Jones</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ShaShares of Eli Lilly & Co. $(LLY)$ were down 5.2% in premarket trading on Monday, two days after the drug maker said additional clinical-trial data reinforced the role its experimental Alzheimer's ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":null,"article_id":"2119912637","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2119912637","pubTimestamp":1615808640,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"ShaShares of Eli Lilly & Co. $(LLY)$ were down 5.2% in premarket trading on Monday, two days after t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"礼来公司的股票在分享了关于其阿尔茨海默病候选药物的更多临床数据后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":0.9},"content_text":"ShaShares of Eli Lilly & Co. $(LLY)$ were down 5.2% in premarket trading on Monday, two days after the drug maker said additional clinical-trial data reinforced the role its experimental Alzheimer's disease drug can play in slowing decline among people with early symptomatic forms of the disease. The data was published in the New England Journal of Medicine on Saturday, and it examined results from a Phase 2 study that found donanemab could reduce decline by 32% when compared against placebo at 76 weeks. Though the study met the primary endpoint, the researchers said that the secondary findings from the trial had mixed results. \"If these results are confirmed in the larger study now in progress, donanemab could offer the potential for a disease-modifying therapy that can help patients maintain cognitive abilities and their independence longer,\" Dr. Howard Fillit, chief science officer of the Alzheimer's Drug Discovery Foundation, said in a statement. Lilly's stock is up 49.3% over the past year, while the broader S&P 500 has gained 58.9%.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":322287812,"gmtCreate":1615810630536,"gmtModify":1704786848129,"author":{"id":"3559703102628596","authorId":"3559703102628596","authorIdStr":"3559703102628596","name":"kenneeth","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3559703102628596"},"htmlText":"Test","listText":"Test","text":"Test","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/322287812","repostId":2119912637,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":322287044,"gmtCreate":1615810615288,"gmtModify":1704786847636,"author":{"id":"3569219134050469","authorId":"3569219134050469","authorIdStr":"3569219134050469","name":"HarimauZack","avatar":"https://static.tigerbbs.com/88a30e96c2e3d56490c9d3530efb509f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3569219134050469"},"htmlText":"Nicceeee","listText":"Nicceeee","text":"Nicceeee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/322287044","repostId":2119912637,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":322217720,"gmtCreate":1615809853460,"gmtModify":1704786835768,"author":{"id":"3577610430427001","authorId":"3577610430427001","authorIdStr":"3577610430427001","name":"1nu","avatar":"https://static.tigerbbs.com/15789a74f3eb14371af59c44a8f71041","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577610430427001"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/322217720","repostId":2119912637,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":14,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2119912637"}